Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BHC with free AI briefings, catalyst countdowns, and dilution alerts.

BHC · Bausch Health Companies Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.5B Cash on Hand
CF+ Cash Runway
2.5% Short Interest
$8.4 Analyst Target (5)
Follow BHC by email Get an email when BHC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BHC, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Perfluorohexyloctane
FDA approved May 2023 · Miebo
Dry Eye Phase 4 · NCT06346340 Completed
Rifaximin
FDA approved May 2004 · Xifaxan
Diarrhea Phase 4 · NCT07285785 Recruiting
Bupropion Hydrobromide
FDA approved Apr 2008 · Aplenzin
Major Depressive Disorder Phase 4 · NCT02129751 Not yet recruiting
Plecanatide
FDA approved Jan 2017 · Trulance
Irritable Bowel Syndrome Characterized by Constipation Phase 3 · NCT02387359 Completed
Lifitegrast
FDA approved Jul 2016 · Xiidra
Dry Eye Disease Phase 2 · NCT07128628 Completed
Brodalumab
FDA approved Feb 2017 · Siliq
Breast Cancer Phase 1 · NCT06673329 Recruiting
(Xiidra®) Lifitegrast Ophthalmic Solution 5.0% Ocular Surface Disease Phase 4 · NCT07490535 Not yet recruiting
Miebo four times per day Dry Eye Syndrome (DES) Phase 4 · NCT07650708 Recruiting
High dose budesonide rectal foam Ulcerative Colitis Phase 4 · NCT05976802 Not yet recruiting
IDP-122 Lotion Psoriasis Phase 4 · NCT03987763 Active not recruiting
IDP-118 Lotion Psoriasis Phase 4 · NCT03988439 Completed
Determine the ability of the TearScience™… Dry Eye Phase 4 · NCT07722624 Active not recruiting
Determine the ability of the iTrace™, BOSA™… Dry Eye Phase 4 · NCT07790211 Recruiting
CABTREO is a fixed-combination product of… Acne Vulgaris Phase 4 · NCT07524946 Recruiting
BTOS-HA Ocular Redness Phase 3 · NCT06803654 Completed
IDP-120 Gel Acne Vulgaris Phase 3 · NCT03664752 Completed

Also used in these trials (approved or third-party drugs, not BHC's own candidates): Clindamycin Phosphate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BHC holds $2.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BHC files for a raise →

👥 Who Owns BHC

Insiders 21.1% Other 5%+ holders 19.1% Institutions (325 holders) 59.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
John Paulson
Director
Insider 73,696,831 19.69% 2026-09-30
PAULSON & CO. INC.
10% owner
Insider 73,255,869 19.57% 2025-11-25
Alex Meruelo 5%+ holder (13D) 36,761,788 9.82% 2025-03-31
Icahn Capital LP 5%+ holder (13D) 34,721,118 9.28% 2025-05-20
Goldentree Asset Management LP Institution (13F) 34,665,731 9.26% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 7,748,378 2.07% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 7,444,589 1.99% 2026-09-30
Two Sigma Investments, LP Institution (13F) 7,410,215 1.98% 2026-09-30
Acadian Asset Management. LLC Institution (13F) 7,239,297 1.93% 2026-09-30
MFN Partners Management, LP Institution (13F) 6,000,000 1.60% 2026-09-30
Gendell, Jeffrey L. Institution (13F) 4,189,291 1.12% 2026-09-30
Thomas Appio
Chief Executive Officer, Director
Insider 2,315,374 0.62% 2026-02-27

Share count 374,266,716 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-30
filed 2026-10-02
LEUNG SANDRA
Award (A) 5,789 $5.83 102,859
2026-09-30
filed 2026-10-02
Paulson John
Award (A) 10,720 $5.83 440,962
2026-09-30
filed 2026-10-02
WECHSLER AMY B
Award (A) 1,179 $5.83 316,158
2026-08-19
filed 2026-08-20
Lenar Aimee J.
Sale (S) 36,827 $7.03 334,853
2026-07-17
filed 2026-07-20
Lenar Aimee J.
Tax withholding (F) 5,260 $4.83 371,680

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full BHC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BHC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.